Executive Summary
The May 19, 2026 filing batch for the NASDAQ-100 stream reveals a bifurcated market with strong operational performance at scale (Cisco) contrasting with micro-cap distress (Bravo Multinational, AIM ImmunoTech).
The dominant theme is strategic portfolio repositioning: Cisco delivered a standout 12% YoY revenue beat with 35% net income growth, while Analog Devices and Maui Land & Pineapple are pursuing transformative M&A/asset sales. The XAI Madison Equity Premium Income Fund is executing a strategic sub-adviser addition to diversify its income strategy, signaling a shift toward preferred equity. However, the small-cap names show acute financial strain—Bravo Multinational's net loss widened 82% YoY, and AIM ImmunoTech only recently climbed out of a negative equity position. Insider activity is notably absent across the large-cap filers, while capital allocation actions (Kennametal's debt tender, PayPal's equity plan) suggest a focus on balance sheet management. The forward-looking catalyst calendar is anchored by Immunic's Phase 3 MS trial readout (YE 2026) and ADI's Empower Semiconductor deal closing (H2 2026), offering event-driven opportunities. Overall, the data signals a 'flight to quality' within the NASDAQ-100, where scale, cash flow, and strategic clarity are rewarded, while smaller names face existential refinancing risks.
Materiality, sentiment, and priority are scored by Gunpowder’s analysis pipeline. How we score filings →
Filing types in this digest: 8-K · 10-Q · DEFA14A
Tracking the trend? Catch up on the prior Nasdaq 100 Stocks SEC Filings digest from May 18, 2026.
Investment Signals (11)
-
Revenue surged 12.0% YoY to $15.84B, product revenue up 16.8%, and net income jumped 35.4% to $3.37B (EPS $0.85 vs $0.62). Operating expenses flat YoY, demonstrating operating leverage. However, services revenue declined 1.4% and operating cash flow fell 11.7% for the 9-month period, signaling potential working capital drag. [BULLISH on revenue/margin, BEARISH on cash conversion]
- Analog Devices ↓ (BULLISH)▲
Announced definitive acquisition of Empower Semiconductor (integrated voltage regulators) expected to close H2 2026. No deal terms disclosed, but the move targets high-growth power management—a critical enabler for AI/data center chips. ADI is buying into a secular trend.
- Immunic ↓ (BULLISH)▲
Appointed Michael W. Bonney (ex-Biogen, ex-Cubist CEO, led $9.5B Merck sale) as Board Chair. Phase 3 ENSURE trial for vidofludimus calcium in relapsing MS top-line data due by end of 2026. Bonney's MS expertise (Avonex launch) directly aligns with this catalyst.
-
Board unanimously approved adding PineBridge Investments (MetLife, $741.7B AUM) as sub-adviser for a new preferred equity strategy (20-30% of assets). This diversifies income sources beyond covered calls, potentially reducing volatility. Management fee unchanged at 0.80%. Shareholder vote July 30, 2026. [BULLISH for income diversification]
-
Entered non-binding MOU with County of Maui to sell/lease water assets. County has initiated budget allocations. While non-binding, this represents a potential monetization of non-core assets after a year of discussions. Materiality 6/10. [NEUTRAL-to-BULLISH if deal closes]
-
Launched cash tender offer for all of its 4.625% Senior Notes due 2028, concurrent with a new senior notes offering. This liability management move (refinancing at potentially lower rates) signals proactive balance sheet optimization. No financials disclosed. [BULLISH for credit profile]
- PayPal ↓ (NEUTRAL)▲
Filed S-8 to register shares under 2026 Equity Incentive Award Plan. No new financial data. Routine equity compensation—dilution risk is standard but worth monitoring if grant volumes spike.
-
Disclosed preliminary AUM of ~$219B as of April 30, 2026. No period comparison provided, limiting trend analysis. AUM is a key revenue driver for asset managers; flat/declining AUM would be a concern. [NEUTRAL, requires context]
- ▲
Issued $50M in consolidated obligations (bonds/discount notes) with maturities 2027-2031 and coupons 4.000%-4.350%. Callable structures (European/Bermudan). This is routine funding but signals the Bank's view on rate stability in the 4% range.
- Bravo Multinational ↓ (BEARISH)▲
Net loss widened 81.9% YoY to $129K, driven by 122% increase in board fees and $28.6K legal settlement. Cash surged to $26K from $111 (year-end 2025), but accumulated deficit hit $(96.6M). Stockholders' deficit of $(1.18M).
-
Stockholder equity improved from $(9.8M) to $2.1M (a $11.9M swing). Extended Streeterville Capital note to June 2027 ($1.68M outstanding). Equity base remains tiny, and clinical programs (Ampligen) carry binary risk. [NEUTRAL-to-BEARISH]
Risk Flags (8)
- Bravo Multinational / Financial Distress↓ [HIGH RISK]▼
Net loss increased 81.9% YoY, board fees surged 122%, and accumulated deficit reached $(96.6M). Stockholders' deficit of $(1.18M) and total liabilities of $1.21M vs cash of $26K. The company is burning cash with no revenue stream identified.
- AIM ImmunoTech / Thin Capitalization↓ [HIGH RISK]▼
Despite the $11.9M equity improvement, total equity is only $2.1M with a $1.68M debt obligation. The company's clinical-stage pipeline (Ampligen) has no approved products. Any clinical failure or financing delay could push equity back negative.
- Cisco Systems / Cash Flow Deterioration↓ [MODERATE RISK]▼
Operating cash flow declined 11.7% for the 9-month period despite 12% revenue growth. This divergence suggests working capital absorption (higher inventory, lower deferred revenue). If persistent, it could pressure FCF and dividend/buyback capacity.
- Maui Land & Pineapple / Deal Failure Risk↓ [MODERATE RISK]▼
The MOU is non-binding with 'no assurance a definitive agreement will be reached.' The County of Maui has budget allocations, but political/regulatory hurdles could derail the sale. If the deal falls through, MLP remains a small-cap real estate play with limited liquidity.
-
The tender offer for 4.625% notes due 2028 and concurrent new issuance could signal higher leverage or an attempt to push out maturities. If the new notes carry a higher coupon or tighter covenants, credit metrics could weaken. [LOW-to-MODERATE RISK]
- PayPal / Equity Dilution↓ [LOW RISK]▼
The S-8 registration for the 2026 Equity Incentive Plan could lead to shareholder dilution if large equity grants are awarded. While standard for tech companies, the quantum of shares registered is not disclosed—watch for insider selling post-vesting.
- XAI Madison / Shareholder Vote Risk↓ [LOW RISK]▼
The PineBridge sub-adviser addition requires shareholder approval at the July 30, 2026 special meeting. If voted down, the fund's strategic shift is blocked, and MCN remains a pure covered call fund in a rising rate environment.
- Acadian Asset Management / AUM Stagnation↓ [MODERATE RISK]▼
Preliminary AUM of ~$219B with no YoY/QoQ comparison. If this represents a decline from prior periods, it would signal net outflows or market depreciation, pressuring fee revenue. The lack of comparative data is itself a red flag.
Opportunities (8)
- Immunic / Phase 3 Catalyst↓ (OPPORTUNITY)◆
Michael Bonney's appointment as Chair (ex-Biogen MS expert) directly aligns with the upcoming ENSURE trial readout for vidofludimus calcium in relapsing MS (YE 2026). If positive, the drug's dual mechanism (Nurr1 activator + DHODH inhibitor) offers differentiation. Pre-readout positioning could yield significant upside.
- Analog Devices / Empower Semiconductor Acquisition↓ (OPPORTUNITY)◆
ADI is acquiring a key player in integrated voltage regulators—a critical component for power-hungry AI chips and data centers. The deal closes H2 2026. If ADI can cross-sell Empower's technology into its existing industrial/automotive base, revenue synergies could exceed deal costs.
- Cisco Systems / Margin Expansion Play↓ (OPPORTUNITY)◆
Q3 FY2026 gross margin improved to $10.08B (from $9.28B), and operating expenses were flat YoY despite 12% revenue growth. If Cisco sustains this operating leverage, EPS could beat consensus. The 35.4% net income jump suggests margin recovery is underway.
- ◆
The addition of PineBridge's preferred equity strategy (20-30% of assets) could boost the fund's yield and reduce correlation to equity options markets. With MetLife's $741.7B AUM backing, PineBridge brings institutional-grade credit analysis. The July 30 vote is a catalyst.
- Maui Land & Pineapple / Asset Monetization↓ (OPPORTUNITY)◆
If the MOU with the County of Maui converts to a definitive agreement, MLP could unlock significant value from its water infrastructure assets. The County's budget allocation suggests seriousness. A sale/lease would provide cash for reinvestment or special dividends.
- Kennametal / Refinancing Arbitrage↓ (OPPORTUNITY)◆
The tender offer for 4.625% notes due 2028, paired with a new issuance, could lower interest costs if the new notes price below 4.625%. This would improve net income and free cash flow. Watch the pricing of the new notes for the arbitrage opportunity.
-
The $50M issuance of callable bonds with coupons 4.000%-4.350% (maturities 2027-2031) offers a relatively attractive yield in a stable rate environment. The FHLB system's joint-and-several liability structure provides implicit government backing. [OPPORTUNITY for fixed income investors]
- AIM ImmunoTech / Turnaround Potential↓ (SPECULATIVE OPPORTUNITY)◆
The $11.9M equity improvement and note extension to June 2027 give the company breathing room. If Ampligen shows positive data in ongoing trials, the stock could re-rate significantly from a distressed valuation. High risk, high reward.
Sector Themes (6)
- Large-Cap Tech Dominance◆
Cisco's 12% revenue growth and 35% net income surge contrast sharply with micro-cap distress (Bravo Multinational -82% net loss). The NASDAQ-100's large caps are leveraging scale for margin expansion, while smaller names struggle with cash burn. Implication: Favor large-cap tech with proven operating leverage.
- Strategic M&A in Power Management◆
Analog Devices' acquisition of Empower Semiconductor signals a consolidation trend in power management ICs, driven by AI/data center demand. This follows other recent deals in the space. Implication: Expect more M&A in analog/power semi as companies seek to offer integrated solutions.
- Income Strategy Diversification◆
XAI Madison's addition of a preferred equity sub-adviser reflects a broader trend of closed-end funds diversifying away from single-asset-class strategies. The move aims to reduce volatility and enhance yield. Implication: CEFs with multi-strategy approaches may outperform single-strategy peers.
- Balance Sheet Repair vs. Growth◆
Kennametal's debt tender and AIM ImmunoTech's note extension show a focus on liability management. Meanwhile, Cisco is investing in growth. The divergence suggests a 'barbell' approach: cash-rich companies invest, while leveraged firms repair. Implication: Favor companies with strong balance sheets that can invest through the cycle.
- Biotech Catalyst Concentration◆
Immunic's Phase 3 MS trial readout (YE 2026) and Bonney's appointment highlight a binary event-driven opportunity in biotech. With limited other biotech filings in this batch, the sector's risk/reward is concentrated in a few late-stage catalysts. Implication: Position for specific trial readouts rather than broad sector exposure.
- Real Estate / Infrastructure Monetization◆
Maui Land & Pineapple's potential sale of water assets to the County of Maui reflects a growing trend of land-rich companies monetizing infrastructure for housing development. Government budget allocations add credibility. Implication: Look for similar asset-light plays in land-holding companies with municipal ties.
Watch List (8)
- 👁
Phase 3 ENSURE trial top-line data for vidofludimus calcium in relapsing MS expected by end of 2026. New Chair Michael Bonney's MS expertise adds credibility. Watch for any data updates or regulatory interactions before YE.
-
Empower Semiconductor acquisition expected to close H2 2026. Watch for HSR clearance updates and any disclosure of deal terms (valuation, expected accretion). Also monitor for competing bids.
-
Special shareholder meeting on or about July 30, 2026 to vote on PineBridge sub-adviser addition. Watch for proxy materials and institutional shareholder voting intentions.
-
MOU with County of Maui for water asset sale/lease. Watch for definitive agreement announcement or termination. County budget allocations are a positive signal but non-binding nature creates uncertainty.
-
Q4 FY2026 earnings (expected Aug 2026). Watch for sustainability of 12% revenue growth, services revenue stabilization, and operating cash flow recovery. Any guidance change will be material.
-
Tender offer for 4.625% notes due 2028 and new senior notes pricing. Watch for the coupon on new notes and any change in leverage ratios. The tender offer expiration date is key.
-
Note maturity extended to June 30, 2027. Watch for clinical data updates on Ampligen and any additional equity/debt financing. The small equity base ($2.1M) makes it vulnerable to dilution.
-
Cash position of $26K and accumulated deficit of $(96.6M). Watch for any going concern disclosure, reverse split announcements, or financing attempts. The stock is at high risk of delisting.
Filing Analyses
(12)
19-05-2026
Maui Land & Pineapple Company (MLP) entered a non-binding Memorandum of Understanding (MOU) with the County of Maui to negotiate the sale or lease of certain real property and water infrastructure assets in West Maui and Upcountry Maui. The MOU follows over a year of discussions and includes monetary and non-monetary consideration such as water credits and land use support to facilitate housing development. However, the MOU is non-binding and there is no assurance a definitive agreement will be reached.
- · On September 10, 2025, MLP formed a sub-committee led by Ken Ota to explore strategic sale of water-related assets.
- · The MOU includes conditions that must be satisfied before a definitive agreement.
- · The County of Maui has initiated budget allocations toward the potential purchase.
- · Assets are expected to be valued based on professional appraisals.
19-05-2026
Immunic, Inc. announced the appointment of Michael W. Bonney as Chair of its Board of Directors effective May 16, 2026. Bonney brings over 30 years of biopharmaceutical leadership, including key roles at Biogen (Avonex launch) and as CEO of Cubist Pharmaceuticals. Simona Skerjanec transitions from Interim Chair to board member. The appointment comes ahead of phase 3 ENSURE trial readouts for vidofludimus calcium in relapsing MS, expected by end of 2026.
- · Bonney played key role in launch and growth of Avonex (multiple sclerosis) and led Cubist through acquisition by Merck for ~$9.5B.
- · Phase 3 ENSURE trials for vidofludimus calcium in relapsing MS top-line data expected by end of 2026.
- · Vidofludimus calcium is a Nurr1 activator and DHODH inhibitor with neuroprotective, anti-inflammatory, and anti-viral effects.
- · Immunic also has earlier-stage programs IMU-856 and IMU-381 targeting neurodegenerative and autoimmune diseases.
19-05-2026
PayPal Holdings, Inc. filed an S-8 registration statement on May 19, 2026 to register shares under the 2026 Equity Incentive Award Plan. The filing incorporates by reference prior SEC filings and includes standard indemnification provisions for directors and officers. No new financial data or material business changes were disclosed.
- · The S-8 registration statement was filed on May 19, 2026.
- · It registers shares under the PayPal Holdings, Inc. 2026 Equity Incentive Award Plan.
- · The filing incorporates by reference the 2025 10-K, Q1 2026 10-Q, and several 8-Ks from 2026.
- · Indemnification provisions for directors and officers are included as per Delaware law and company bylaws.
- · Signatories include CEO Enrique Lores, CFO Jamie Miller, and CAO Christopher Natali.
19-05-2026
Cisco reported strong Q3 FY2026 results with total revenue of $15,841M, up 12.0% YoY from $14,149M, driven by product revenue growth of 16.8% to $12,117M. Net income rose 35.4% to $3,373M ($0.85 per diluted share) from $2,491M ($0.62 per diluted share). However, services revenue declined 1.4% YoY to $3,724M, and operating cash flow decreased 11.7% to $8,791M for the nine-month period, reflecting higher inventory and lower deferred revenue.
- · Gross margin for Q3 FY2026 was $10,080M, up from $9,278M in Q3 FY2025.
- · Total operating expenses for Q3 FY2026 were $6,120M, relatively flat compared to $6,076M in Q3 FY2025.
- · Restructuring and other charges were a credit of $1M in Q3 FY2026 versus a charge of $34M in Q3 FY2025.
- · Interest and other income (loss), net was $79M in Q3 FY2026, compared to a loss of $255M in Q3 FY2025.
- · Provision for income taxes increased to $666M in Q3 FY2026 from $456M in Q3 FY2025.
- · Cash dividends declared were $0.42 per common share in Q3 FY2026, up from $0.41 in Q3 FY2025.
- · Share repurchases totaled $1,252M in Q3 FY2026, compared to $1,504M in Q3 FY2025.
- · Inventories increased to $4,708M at April 25, 2026 from $3,164M at July 26, 2025.
- · Short-term debt rose to $11,932M from $5,232M at July 26, 2025.
- · Long-term debt decreased to $19,371M from $22,861M at July 26, 2025.
19-05-2026
XAI Madison Equity Premium Income Fund (MCN) announced that its Board of Trustees has unanimously approved, subject to shareholder approval, the addition of PineBridge Investments as an additional investment sub-adviser. PineBridge will manage a new preferred equity strategy, while Madison Asset Management continues to manage the existing covered call equity strategy. The fund's name will change to 'XAI Equity Premium Income Fund', and a special shareholder meeting is scheduled for on or about July 30, 2026. The investment advisory fee remains unchanged at 0.80% of average daily managed assets.
- · The Board of Trustees, including Independent Trustees, unanimously approved the PineBridge sub-advisory agreement.
- · PineBridge became part of MetLife Investment Management in December 2025.
- · The fund's investment objective remains unchanged: high level of current income and gains, with secondary objective of capital appreciation.
- · XAI will oversee allocation between the two strategies with input from both sub-advisers.
- · XAI will pay sub-advisory fees to both Madison and PineBridge from the 0.80% advisory fee.
- · The special shareholder meeting is expected on or about July 30, 2026.
- · Current portfolio managers will continue for the covered call equities strategy.
- · The proxy statement will be available free at www.sec.gov when filed.
- · No financial performance data or period-over-period comparisons are provided in this filing.
19-05-2026
AIM ImmunoTech reported a significant increase in stockholder equity from a deficit of approximately $9.8 million as of December 31, 2025, to positive equity of approximately $2.1 million as of March 31, 2026, an improvement of about $11.9 million. The company also extended the maturity date of its promissory note with Streeterville Capital, LLC to June 30, 2027, with an outstanding balance of approximately $1.68 million. While the equity improvement and note extension enhance financial flexibility, the company still has a relatively small equity base and a material debt obligation, and its clinical programs remain subject to significant risks and uncertainties.
- · The promissory note was originally issued on February 16, 2024.
- · The company has raised additional equity-generating funds through various transactions since March 31, 2026.
- · The company's lead product is Ampligen (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator.
- · The company is focused on the treatment of late-stage pancreatic cancer.
19-05-2026
Acadian Asset Management Inc. filed an 8-K on May 19, 2026, disclosing preliminary assets under management (AUM) of approximately $219 billion as of April 30, 2026, in connection with its Investor Forum. The filing includes a press release and management presentation as exhibits. No period-over-period comparisons or additional financial metrics were provided, limiting the ability to assess performance trends.
- · The filing is under Items 7.01 (Regulation FD Disclosure) and 9.01 (Financial Statements and Exhibits).
- · Exhibits include a press release (99.1) and an Investor Forum management presentation (99.2), both dated May 19, 2026.
- · The AUM figure is preliminary and unaudited.
19-05-2026
Kennametal Inc. announced on May 19, 2026, that it has commenced a cash tender offer to purchase any and all of its 4.625% Senior Notes due 2028, and also launched an underwritten public offering of senior notes. The tender offer is subject to terms in an Offer to Purchase dated the same day. No financial figures or period comparisons were provided in this filing.
- · The tender offer is for any and all of the Company's 4.625% Senior Notes due 2028.
- · The underwritten public offering of senior notes has been commenced concurrently with the tender offer.
- · The press release is filed as Exhibit 99.1 and incorporated by reference.
19-05-2026
Bravo Multinational Inc. (BRVO) reported a net loss of $129,175 for Q1 2026, up 81.9% from a $71,019 loss in Q1 2025, driven by a 122% increase in board of director fees to $146,650 and a $28,588 legal settlement expense. Cash and cash equivalents surged to $26,051 from $111 at year-end 2025, while total liabilities rose to $1,210,813 from $1,055,698, and the accumulated deficit widened to $(96,563,824). The company remains in a stockholders' deficit of $(1,184,762).
- · Professional fees decreased 64.9% to $8,892 in Q1 2026 from $25,350 in Q1 2025.
- · General and administrative expenses rose 15.7% to $2,221 from $1,919.
- · Net cash provided by operating activities was $24,190 in Q1 2026 vs. $(25,093) used in Q1 2025.
- · Due to related parties increased to $371,053 from $369,303.
- · Accrued board of directors fees rose to $702,050 from $555,400.
- · No revenue was reported for either period.
19-05-2026
Federal Home Loan Bank of San Francisco filed an 8-K disclosing the issuance of consolidated obligations (bonds and discount notes) on trade dates May 13 and May 15, 2026, with total par value of $50 million. These obligations are joint and several liabilities of the eleven Federal Home Loan Banks and are not guaranteed by the U.S. government. The filing provides details on three specific bond issuances with maturities ranging from 2027 to 2031 and fixed coupon rates between 4.000% and 4.350%.
- · Consolidated obligations are joint and several obligations of all eleven Federal Home Loan Banks and are not guaranteed by the U.S. government.
- · The bonds are callable with European or Bermudan call styles, and all have fixed constant coupon rates.
- · The filing excludes discount notes with maturity of one year or less issued in ordinary course.
- · The Bank may change its method of reporting issuance or assumption of consolidated obligations at any time.
19-05-2026
Analog Devices Inc. (ADI) announced a definitive agreement to acquire Empower Semiconductor, a provider of integrated voltage regulators and power management solutions. The transaction is expected to close in the second half of calendar year 2026, subject to customary closing conditions including HSR antitrust clearance. No financial terms of the acquisition were disclosed in the filing.
- · The acquisition was announced via a joint press release on May 19, 2026 (Exhibit 99.1).
- · Closing is expected in H2 calendar year 2026, pending HSR Act waiting period expiration.
- · The filing is furnished under Item 7.01 (Regulation FD) and is not deemed 'filed' for Section 18 Exchange Act purposes.
Get daily alerts with 11 investment signals, 8 risk alerts, 8 opportunities and full AI analysis of all 12 filings
$30/mo after a 14-day free trial — no credit card required. See pricing or explore intelligence streams.
More from: Nasdaq 100 Stocks SEC Filings
🇺🇸 More from United States
View all →May 28, 2026
US Pre-Market SEC Filings Roundup — May 28, 2026
US Pre-Market SEC Filings Roundup
May 27, 2026
US Pre-Market SEC Filings Roundup — May 27, 2026
US Pre-Market SEC Filings Roundup
May 27, 2026
S&P 500 Technology Sector SEC Filings — May 27, 2026
S&P 500 Technology Sector SEC Filings
May 27, 2026
Orphan Drug Approvals — May 27, 2026
Orphan Drug Approvals